Segment Disclosure

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Segment Disclosure

12.Segment disclosure:

The Company operates as a single reportable segment dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need. The Company has no products approved for sale and has not generated any revenue from product sales. The Company’s Chief Executive Officer acts as the chief operating decision maker and manages the Company’s operations on a consolidated basis, using net loss to assess performance and allocate resources. The accounting policies for the operating segment are consistent with the Company’s policies for the consolidated financial statements. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets, with a majority of these assets located in the United States.

The following table presents information about reported segment revenues, significant segment expenses, and segment loss:

	Three Months Ended June 30,						Six Months Ended June 30,
	2025			2024			2025			2024
Collaboration revenue	$	—		$	—		$	7,500		$	—
Less:
Direct external research and development costs
Azetukalner		43,405			23,344			74,906			46,557
Pre-clinical, discovery and other programs		6,111			6,169			11,078			9,830
Personnel-related expenses		22,386			16,053			45,026			30,907
Stock-based compensation expense		13,713			14,716			25,887			24,116
Other research and development costs		2,600			3,163			6,025			6,177
Other general and administrative costs		6,014			5,659			11,545			10,558
Interest income		(7,199	)		(10,837	)		(15,282	)		(22,192	)
Other segment items(1)		(2,324	)		(343	)		(1,932	)		(98	)
Net loss	$	(84,706	)	$	(57,924	)	$	(149,753	)	$	(105,855	)

(1)Other segment items include foreign exchange gain and income tax (recovery) expense.